Non-responders to Peptide Receptor Radionuclide Therapy (PRRT) – A single center retrospective analysis

#3635

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) has become the standard of care for patients (pts) with positive somatostatin receptor image, grade (G)1/2 gastrointestinal (GI) neuroendocrine tumors (NETs) after Somatostatin Analogues (SSAs) failure.

Aim(s): We aim to analyse features of PRRT non-responders (NRs) to identify some other selection criteria to stratify the pts to the treatments.

Materials and methods: We retrospectively analysed G1/2 GI-NET pts treated with PRRT at our institute from 11/2019 to 07/2022, excluding those with ongoing PRRT or lost to follow-up.

Conference:

Presenting Author: Laffi A

Authors: Laffi A, Rodari M, Lania A, Zerbi A, Elisabetta L,

Keywords: PRRT, neuroendocrine tumor, NET, Nuclear Medicine,